Translational science, applied with discipline
We pair biologics platforms with translational research and global clinical partnerships, focusing our resources where we can make a measurable difference to patients.
Around 13% of revenue is reinvested into R&D each year. Our Seoul research centre works alongside academic and clinical collaborators across Asia, Europe and North America to move candidates from bench to bedside.
R&D Center · SeoulWhere our science concentrates
Biosimilars
Affordable, high-quality biologic alternatives in immunology and oncology.
Metabolic disease
Long-acting therapies for diabetes and obesity-related conditions.
Oncology
Early-stage candidates targeting hard-to-treat solid tumours.
Anti-infectives
Next-generation antivirals and antibacterials for global health needs.
Selected development programmes
| Programme | Therapeutic area | Stage |
|---|---|---|
| SGM-204 | Metabolic — long-acting injectable | Phase III |
| SGM-118 | Immunology — biosimilar | Phase III |
| SGM-330 | Oncology — monoclonal antibody | Phase II |
| SGM-407 | Anti-infective — broad-spectrum antiviral | Phase I |
| SGM-512 | Dermatology — specialty biologic | Preclinical |
Programme names and stages are illustrative for the purposes of this corporate website.
Partner with our research teams.
We welcome academic, clinical and commercial collaborations across our focus areas.